3-甲氧基-4-叔丁基苯甲酸 | 79822-46-1

• 物质功能分类: 化学试剂 - 有机试剂 - 芳香酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-甲氧基-4-叔丁基苯甲酸
• 英文名称: 4-tert-butyl-3-methoxybenzoic acid
• 英文别名: 3-methoxy-4-tert-butylbenzoic acid
• CAS: 79822-46-1
• 化学式: C₁₂H₁₆O₃
• mdl: MFCD06656116
• 分子量: 208.257
• InChiKey: CSJQLIMNCLFPLZ-UHFFFAOYSA-N

物化性质

• 熔点：
  150-151 °C
• 沸点：
  334.7±35.0 °C(Predicted)
• 密度：
  1.080±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2918990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Name:	4-tert-Butyl-3-methoxybenzoic acid Material Safety Data Sheet
Synonym:	None Known
CAS:	79822-46-1

Section 1 - Chemical Product MSDS Name:4-tert-Butyl-3-methoxybenzoic acid Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
79822-46-1	4-tert-Butyl-3-methoxybenzoic acid	ca. 100	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid.
Skin:
In case of contact, flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical aid if irritation develops and persists. Wash clothing before reuse.
Ingestion:
If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions. Provide ventilation. Vacuum or sweep up material and place into a suitable, dry disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 79822-46-1: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 150-152 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: Soluble.
Specific Gravity/Density:
Molecular Formula: C12H16O3
Molecular Weight: 208.26

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not currently available.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 79822-46-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-tert-Butyl-3-methoxybenzoic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 79822-46-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 79822-46-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 79822-46-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-甲氧基-4-叔丁基苯甲酸 在 N-溴代丁二酰亚胺(NBS) 、 四(三苯基膦)钯 、 二苯基膦叠氮化物 、 水 、 溴 、 sodium carbonate 、 溶剂黄146 、 三乙胺 、 potassium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 58.25h， 生成 N-[4-(8-bromo-6-tert-butyl-5-methoxy-3-quinolyl)phenyl]methanesulfonamide
  参考文献：
  名称：

  Discovery of N-[4-[6-tert-Butyl-5-methoxy-8-(6-methoxy-2-oxo-1H-pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide (RG7109), a Potent Inhibitor of the Hepatitis C Virus NS5B Polymerase

  摘要：

  In the past few years, there have been many advances in the efforts to cure patients with hepatitis C virus (HCV). The ultimate goal of these efforts is to develop a combination therapy consisting of only direct-antiviral agents (DAAs). In this paper, we discuss our efforts that led to the identification of a bicyclic template with potent activity against the NS5B polymerase, a critical enzyme on the life cycle of HCV. In continuation of our exploration to improve the stilbene series, the 3,5,6,8-tetrasubstituted quinoline core was identified as replacement of the stilbene moiety. 6-Methoxy-2(1H)-pyridone was identified among several heterocyclic headgroups to have the best potency. Solubility of the template was improved by replacing a planar aryl linker with a saturated pyrrolidine. Profiling of the most promising compounds led to the identification of quinoline 41 (RG7109), which was selected for advancement to clinical development.

  DOI：

  10.1021/jm401329s
• 作为产物：
  描述：

  2-叔丁基-5-甲基苯甲醚 在 potassium permanganate 作用下， 生成 3-甲氧基-4-叔丁基苯甲酸
  参考文献：
  名称：

  N-酰基吡咯烷的不对称合成抑制HCV聚合酶

  摘要：

  描述了多公斤级的高度取代的N-酰基吡咯烷的实际不对称合成。构建三个立体中心的关键步骤是丙烯酸甲酯和由1-亮氨酸t制备的亚氨基酯的[3 + 2]环加成反应。丁酯盐酸盐和2-噻唑甲醛。通过乙酸银和金鸡纳生物碱（特别是对苯二酚）的络合物，具有完全的非对映异构体控制和高达87％的对映体控制，可实现新型的不对称催化。生物碱既用作配体，又用作形成甲亚胺叶立德或1,3-偶极的基础。实验表明，对苯二酚的羟基是观察到的对映选择性的关键元素。环加成方法也适用于甲基乙烯基酮，根据所使用的反应条件，可以接触到4-乙酰基吡咯烷的α-或β-受体。该合成还强调了有效的N酰化，选择性O-对N-甲基化，以及由NaB（OAc）3 H催化的NaBH 4 -MeOH独特的酯还原反应，不仅可以实现出色的化学选择性，而且还可以避免形成不需要的但热力学上受人欢迎的差向异构体。从1-亮氨酸叔丁酯盐酸盐以七个线性步骤合成高度官能化的靶标，所有三个分离的中间体均为高度结晶。

  DOI：

  10.1021/jo800062c

文献信息

• [EN] PYRAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS<br/>[FR] AMIDES DE PIPÉRIDINE SPIROCYCLIQUES PYRANES UTILISÉS EN TANT QUE MODULATEURS DE CANAUX IONIQUES
  申请人：VERTEX PHARMA

  公开号：WO2013109521A1

  公开（公告）日：2013-07-25

  The invention relates to pyran spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及用作离子通道抑制剂的吡喃螺环哌啶酰胺化合物。本发明还提供了包含本发明化合物的药用可接受组合物，以及使用这些组合物治疗各种疾病的方法。
• [EN] HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS<br/>[FR] AMIDES DE CHROMÈNE HÉTÉROCYCLIQUE-PIPÉRIDINE SPIROCYCLIQUE UTILES COMME MODULATEURS DES CANAUX IONIQUES
  申请人：VERTEX PHARMA

  公开号：WO2011140425A1

  公开（公告）日：2011-11-10

  The invention relates to heterocyclic chromene-spirocyclic piperidine amides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及杂环色烯-螺环哌啶酰胺，用作离子通道的抑制剂。本发明还提供了包含本发明化合物的药用可接受组合物，以及使用这些组合物治疗各种疾病的方法。
• [EN] BENZOXAZINES AS MODULATORS OF ION CHANNELS<br/>[FR] BENZOXAZINES COMME MODULATEURS DES CANAUX IONIQUES
  申请人：VERTEX PHARMA

  公开号：WO2013067248A1

  公开（公告）日：2013-05-10

  The invention relates to benzoxazines useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及可用作离子通道抑制剂的苯并噁嗪。本发明还提供了包含本发明化合物的药用可接受组合物，以及使用这些组合物治疗各种疾病的方法。
• Isonicotinate Ester Catalyzed Decarboxylative Borylation of (Hetero)Aryl and Alkenyl Carboxylic Acids through <i>N</i>-Hydroxyphthalimide Esters
  作者：Wan-Min Cheng、Rui Shang、Bin Zhao、Wei-Long Xing、Yao Fu

  DOI：10.1021/acs.orglett.7b01950

  日期：2017.8.18

  Decarboxylative borylation of aryl and alkenyl carboxylic acids with bis(pinacolato)diboron was achieved through N-hydroxyphthalimide esters using tert-butyl isonicotinate as a catalyst under base-free conditions. A variety of aryl carboxylic acids possessing different functional groups and electronic properties can be smoothly converted to aryl boronate esters, including those that are difficult to

  芳基和链烯基羧酸与双（频哪醇合）二硼的脱羧硼化通过实现Ñ使用-hydroxyphthalimide酯叔异烟酸丁酯在无碱条件下作为催化剂。可以将具有不同官能团和电子特性的各种芳基羧酸平稳地转化为芳基硼酸酯，包括在过渡金属催化下难以脱羧的芳基硼酸酯，从而提供了一种新方法，使羧酸可以用作有机合成中的基础。机理分析表明，该反应通过自由基脱羧产生的瞬态芳基与吡啶稳定的持久性硼基的偶联而进行。氧化还原活性酯的活化可以通过分子内单电子转移（SET）过程，通过吡啶-二硼-邻苯二甲酰亚胺加合物进行，并说明了无碱反应条件。
• HETEROCYCLIC ANTIVIRAL COMPOUNDS
  申请人：Li Jim

  公开号：US20100111900A1

  公开（公告）日：2010-05-06

  Compounds having the formula I wherein R 1 , R 2 , R 3a , R 3b , R 3c , R 4 , R 5 and p are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.

  具有以下化学式I的化合物，其中R1、R2、R3a、R3b、R3c、R4、R5和p的定义如本文所述，是丙型肝炎病毒NS5b聚合酶抑制剂。还公开了用于治疗HCV感染和抑制HCV复制的组合物和方法。